计算溶液所需的质量、体积或浓度。
这是演示店铺,请务下单付款,避免造成你的财物损失。
为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
A125227-5mg |
5mg |
现货 ![]() |
| |
A125227-10mg |
10mg |
现货 ![]() |
| |
A125227-50mg |
50mg |
现货 ![]() |
|
别名 | MSC1936369B;AS703026 |
---|---|
英文别名 | MSC1936369B;AS-703026;AS 703026;N-[(2S)-2,3-Dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-4-pyridinecarboxamide |
规格或纯度 | ≥98% |
英文名称 | Pimasertib (AS-703026) |
生化机理 | AS703026 is a highly selective and potent noncompetitive inhibitor of MEK1 and MEK2 (IC50 = 5-11 nM). |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
产品介绍 |
Pimasertib (AS-703026) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 μM in MM cell lines.A potent inhibitor of MEK1 and MEK2. Pimasertib (AS-703026) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 μM in MM cell lines. |
IUPAC Name | N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)pyridine-4-carboxamide |
---|---|
INCHI | InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1 |
InChi Key | VIUAUNHCRHHYNE-JTQLQIEISA-N |
Canonical SMILES | C1=CC(=C(C=C1I)F)NC2=C(C=CN=C2)C(=O)NCC(CO)O |
PubChem CID | 44187362 |
分子量 | 431.2 |
PubChem CID | 44187362 |
---|---|
CAS Registry No. | 1236699-92-5 |
ChEMBL Ligand | CHEMBL2107832 |
Reactome Reaction | R-HSA-9657606 |
Reactome Drug | R-ALL-9657523 |
RCSB PDB Ligand | QOA |
溶解性 | DMSO ≥83mg/mL Water <1.2mg/mL Ethanol ≥2.6mg/mL |
---|
输入批号以搜索COA:
1. Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D et al.. (2010) Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.. Br J Haematol, 149 (4): (537-49). [PMID:20331454] |
2. Yoon J, Koo KH, Choi KY. (2011) MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.. Cancer Res, 71 (2): (445-53). [PMID:21118963] |
3. Chang-Yew Leow C, Gerondakis S, Spencer A. (2013) MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.. Blood Cancer J, 3 (13): (e105). [PMID:23524590] |